Zoladex

Meningioma

Nader SanaiEarly Phase 1Active

C

38/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 81/ 100

Competitive context

13 Active assets in the Meningioma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Essen Biotech	Phase 2	B
Fludarabine Essen Biotech	Phase 2	B
Rvp-001 Reveal Pharmaceuticals Inc.	Phase 2	B
Anti-Ny Eso-1 Mtcr Pbl National Cancer Institute (NCI)	Phase 2	B
Oxodotreotide Fundación de investigación HM	Phase 1/2	CC

View all 14 →

Same molecule, other indications

Zoladex is also rated in:

HR+/HER2- Breast CancerDormant

BB

Indicative ·

71 / 100

prostate neoplasmDormant

BB

Indicative ·

69 / 100

prostate adenocarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.